SCHEMBL4229112

SCHEMBL4229112

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(C(N)=O)cc2)c(OC)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.57
TAS1R3 Q7RTX0 1/20 0.52
TAS1R1 Q7RTX1 1/20 0.52
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
MAPT P10636 3/20 0.51
GAA P10253 2/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
ALDH1A1 P00352 2/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
TP53 P04637 1/20 0.50
HTT P42858 1/20 0.50
POLB P06746 2/20 0.47
FPR2 P25090 1/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
MTNR1B P49286 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236662 0.90 PKM (0.50) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4228811 0.89 PKM (0.60) PKMTAS1R3TAS1R1MEN1KMT2A
Ammonia Solution, Strong SCHEMBL4235457 0.88 PKM (0.58) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4238631 0.87 MEN1 (0.52) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4226971 0.87 PKM (0.60) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4683708 0.87 PKM (0.63) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4229305 0.87 PKM (0.60) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL5149842 0.87 PKM (0.63) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4233456 0.87 PKM (0.63) PKMTAS1R3TAS1R1MEN1KMT2A
SCHEMBL4236704 0.85 PKM (0.66) PKMTAS1R3TAS1R1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP claimed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885TAS1R3 1436/4885TAS1R1 1073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.